SG171602A1 - Use of antisecretory factors for treating intraocular hypertension - Google Patents

Use of antisecretory factors for treating intraocular hypertension

Info

Publication number
SG171602A1
SG171602A1 SG201102876-8A SG2011028768A SG171602A1 SG 171602 A1 SG171602 A1 SG 171602A1 SG 2011028768 A SG2011028768 A SG 2011028768A SG 171602 A1 SG171602 A1 SG 171602A1
Authority
SG
Singapore
Prior art keywords
antisecretory
intraocular hypertension
antisecretory factors
factors
prevention
Prior art date
Application number
SG201102876-8A
Other languages
English (en)
Inventor
Hans-Arne Hansson
Stefan Lange
Eva Jennische
Original Assignee
Lantmaennen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmaennen As Faktor Ab filed Critical Lantmaennen As Faktor Ab
Publication of SG171602A1 publication Critical patent/SG171602A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG201102876-8A 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension SG171602A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0600932 2006-04-27

Publications (1)

Publication Number Publication Date
SG171602A1 true SG171602A1 (en) 2011-06-29

Family

ID=38561776

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201102876-8A SG171602A1 (en) 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension

Country Status (18)

Country Link
US (2) US8207296B2 (pt)
EP (2) EP2015767B1 (pt)
JP (2) JP5284948B2 (pt)
KR (1) KR20090040404A (pt)
CN (2) CN101432013B (pt)
AU (1) AU2007244004B2 (pt)
BR (1) BRPI0710959B8 (pt)
CA (2) CA2650344C (pt)
DK (2) DK2015767T3 (pt)
ES (2) ES2561945T3 (pt)
IL (1) IL194773A (pt)
MX (1) MX2008013769A (pt)
NZ (2) NZ598426A (pt)
PL (2) PL2468292T3 (pt)
RU (1) RU2458703C2 (pt)
SG (1) SG171602A1 (pt)
WO (1) WO2007126364A2 (pt)
ZA (1) ZA200809115B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101432013B (zh) * 2006-04-27 2015-01-07 兰特门内阿斯-法克托尔公司 抗分泌因子对于治疗高眼压的应用
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
JP5820277B2 (ja) * 2009-02-11 2015-11-24 ラントメネン・アーエス−ファクトール・アーベー 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
WO2013050795A1 (en) * 2011-10-03 2013-04-11 Femtonics Kft. Use of photoactive compounds
CN105025916B (zh) * 2012-12-20 2020-03-10 兰特门内阿斯-法克托尔公司 抗分泌因子(af)在胶质母细胞瘤治疗中的用途
CN107949392B (zh) 2015-07-10 2022-10-11 兰特门内阿斯-法克托尔公司 用于生产含高含量af-16的蛋黄的方法
US11407796B2 (en) 2016-07-18 2022-08-09 Lantmännen As-Faktor Ab Antisecretory factor 17
CN112368014A (zh) 2018-06-28 2021-02-12 兰特门内医疗公司 抗分泌因子在治疗和/或预防急性呼吸衰竭中的用途
EP3855934A2 (en) 2018-09-28 2021-08-04 Lantmännen Functional Foods AB A consumable product comprising malted dehulled oat
EP3855935A1 (en) 2018-09-28 2021-08-04 Lantmännen Functional Foods AB A consumable product comprising malted wheat
AU2021243735A1 (en) 2020-03-26 2022-10-13 Lantmännen Functional Foods Ab A consumable product comprising malted cereals for promoting recovery at physical activity
US20240148709A1 (en) * 2022-11-08 2024-05-09 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH682716A5 (de) 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
EP0876483A1 (en) * 1996-01-26 1998-11-11 HSC Research and Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
SE506486C2 (sv) 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
CN1335887A (zh) * 1999-06-21 2002-02-13 印坎药物股份有限公司 血管抑制素∶一种Cys－Ser－Val－Thr－Cys－Gly特异性肿瘤细胞粘附受体
RU2192898C1 (ru) * 2001-08-16 2002-11-20 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения герпетического кератита с изъязвлением
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
JP5508846B2 (ja) * 2006-04-27 2014-06-04 ラントメネン・アーエス−ファクトール・アーベー 脂質ラフトの調節
CN104689299B (zh) * 2006-04-27 2020-02-21 兰特门内阿斯-法克托尔公司 抗分泌蛋白对于治疗间室综合症的应用
CN101432013B (zh) * 2006-04-27 2015-01-07 兰特门内阿斯-法克托尔公司 抗分泌因子对于治疗高眼压的应用

Also Published As

Publication number Publication date
AU2007244004B2 (en) 2012-02-09
ZA200809115B (en) 2009-07-29
NZ598426A (en) 2012-08-31
BRPI0710959B8 (pt) 2021-05-25
US8207296B2 (en) 2012-06-26
BRPI0710959A2 (pt) 2012-02-28
CN102633863A (zh) 2012-08-15
EP2468292B1 (en) 2019-12-18
ES2561945T3 (es) 2016-03-01
US20090162296A1 (en) 2009-06-25
CA2650344A1 (en) 2007-11-08
JP5284948B2 (ja) 2013-09-11
IL194773A (en) 2015-07-30
CN101432013B (zh) 2015-01-07
JP2009535329A (ja) 2009-10-01
DK2468292T3 (da) 2020-03-23
AU2007244004A1 (en) 2007-11-08
CA2771087A1 (en) 2007-11-08
EP2015767A2 (en) 2009-01-21
IL194773A0 (en) 2011-08-01
DK2015767T3 (en) 2016-02-08
ES2773945T3 (es) 2020-07-15
WO2007126364A2 (en) 2007-11-08
WO2007126364A8 (en) 2009-07-23
RU2458703C2 (ru) 2012-08-20
EP2015767B1 (en) 2016-01-06
EP2468292A1 (en) 2012-06-27
CN102633863B (zh) 2014-08-06
NZ572255A (en) 2012-03-30
WO2007126364A3 (en) 2008-03-06
CA2771087C (en) 2016-03-15
RU2008146733A (ru) 2010-06-10
CA2650344C (en) 2017-10-31
MX2008013769A (es) 2009-02-03
BRPI0710959B1 (pt) 2018-11-06
US9000125B2 (en) 2015-04-07
US20120283191A1 (en) 2012-11-08
CN101432013A (zh) 2009-05-13
PL2015767T3 (pl) 2016-05-31
JP2012153695A (ja) 2012-08-16
KR20090040404A (ko) 2009-04-24
PL2468292T3 (pl) 2020-08-24
EP2468292B8 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
SG171602A1 (en) Use of antisecretory factors for treating intraocular hypertension
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
WO2009047766A3 (en) Composition and method for the treatment or prevention of glaucoma and ocular hypertension
WO2006124874A3 (en) Inhibitors of b-raf kinase
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2010001169A3 (en) Chemical compounds 251
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
MX2009001062A (es) Agonistas de ep2.
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2008011611A3 (en) Compounds and compositions as itpkb inhibitors
MY138811A (en) Preventive or therapeutic agent for glaucoma
WO2007022947A3 (de) 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
MY150250A (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
WO2007146136A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007045930A3 (en) Modulation of trpv expression levels
EP1251862A4 (en) ORTHALMOLOGICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
WO2008055205A3 (en) Pai-1 binding modulators for the treatment of ocular disorders
WO2008042968A3 (en) Di-fluoro containing compounds as cysteine protease inhibitors